Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Rev Endocr Metab Disord
; 18(4): 411-421, 2017 Dec.
Article
em En
| MEDLINE
| ID: mdl-29080935
ABSTRACT
The management of patients with midgut neuroendocrine tumors (MNET) is rapidly evolving. Current preoperative detection rates of primary tumor sites are higher than ever and progression-free survival in patients with already advanced disease is expanding due to the implementation of novel efficacious treatment strategies. This survival benefit may potentially translate into a need for a multidisciplinary approach to an even more heterogenous variety of clinical conditions, among these, carcinoid syndrome (CS) and carcinoid heart disease (CHD). The latter often triggers substantial morbidity and mortality, hence a systematic screening, an accurate diagnosis, as well as effective interventions are critically important. The rarity of the disease has result in a relative lack of statistically powerful evidence, which in turn may have rendered significant variability between practices. In this regard, despite recent guidelines, the optimal follow-up of patients with CHD remain debatable to some authors, perhaps due to the preponderance of certain schools throughout the manuscript. Herein, we present a concise and practical guidance document on clinical screening and echocardiographic surveillance of patients with CHD based on a comprehensive review of the literature, and complemented by our experience at the Center for Carcinoid and Neuroendocrine Tumors at The Mount Sinai Hospital.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença Cardíaca Carcinoide
/
Tumor Carcinoide
/
Ecocardiografia
/
Tumores Neuroendócrinos
/
Neoplasias Intestinais
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Humans
Idioma:
En
Revista:
Rev Endocr Metab Disord
Assunto da revista:
ENDOCRINOLOGIA
/
METABOLISMO
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Estados Unidos